Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Kymera Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 181
- +6 vs. Q3 2024
- Shares held
- 71.7M
- +2.69M (+3.9%) vs. Q3 2024
- Total value
- $2.89B
- −$382.7M (−11.7%) vs. Q3 2024
- New holders
- 34
- 60 more added
- Sold out
- 28
- 60 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYMR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 276 | $11.1B |
| Q1 2026 | 256 | $8.01B |
| Q4 2025 | 255 | $6.99B |
| Q3 2025 | 210 | $4.58B |
| Q2 2025 | 210 | $3.44B |
| Q1 2025 | 174 | $2.00B |
| Q4 2024 | 181 | $2.89B |
| Q3 2024 | 176 | $3.27B |
| Q2 2024 | 157 | $2.01B |
| Q1 2024 | 164 | $2.70B |
| Q4 2023 | 137 | $1.54B |
| Q3 2023 | 122 | $797.2M |
| Q2 2023 | 129 | $1.34B |
| Q1 2023 | 127 | $1.68B |
| Q4 2022 | 121 | $1.40B |
| Q3 2022 | 128 | $1.15B |
| Q2 2022 | 101 | $973.6M |
| Q1 2022 | 126 | $1.93B |
| Q4 2021 | 128 | $2.76B |
| Q3 2021 | 115 | $2.04B |
| Q2 2021 | 110 | $1.29B |
| Q1 2021 | 97 | $887.2M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Kymera Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Pictet Asset Management Holding SA | 0 | $0 | 0.00% | −4,685−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −3,418−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −2,328−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Values First Advisors, Inc. | 0 | $0 | 0.00% | −1,296−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −800−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| CVA Family Office, LLC | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| PEAK6 Investments LLC | – | – | – | – | Not filed |